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Abstract: Familial Mediterranean fever is an autosomal recessive autoinflammatory disorder 
mainly affecting Mediterranean populations, which is associated with mutations of the MEFV 
gene that encodes pyrin. Functional studies suggest that pyrin is implicated in the maturation and 
secretion of interleukin-1 (IL-1). The IL-1 receptor antagonist or anti-IL-1 monoclonal antibody 
may therefore represent a rational approach for the treatment of the rare patients who are refractory 
to conventional therapy. We report the case of a young female affected by familial Mediterranean 
fever who proved to be resistant to colchicine and was successfully treated with canakinumab.
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Case report
A 30-year-old Bolivian woman with familial Mediterranean fever (FMF) was referred 
to our Centre of Research on Immunopathology and Rare Diseases (CMID) in Novem-
ber 2010 because of remitting fever over a 6-month period, painful symmetrical arthritis 
of the wrists, elbows, and knees without radiographic erosions or deformities, myalgia, 
diarrhea with abdominal pain, and weight loss.
FMF had been diagnosed 7 years before at the Division of Medicine of the Johns 
Hopkins Institute of Baltimore. At that time, the disease was characterized by short-
lived recurrent inflammatory febrile attacks, concurrent with abdominal and chest pain 
and erysipelas-like skin lesions.
She had been under regular treatment with colchicine 1 mg daily since diagnosis 
with a good response for 6 years. In 2008, she moved to Italy to continue her educa-
tion, and in June 2010, her attacks recurred with different clinical features including 
predominant articular symptoms, fever, and abdominal crises, despite continued 
administration of colchicine (1 mg/day).
In August 2010, she was referred to our centre (CMID). She reported frequent 
attacks (three episodes a week, 12 crises in the preceding month) dominated by more 
severe arthralgia and abdominal pain. During intercritical periods, the symptoms 
diminished but did not cease altogether as had previously been the case. Her quality of 
life was severely compromised with decreasing body weight (from 56 kg to 49 kg).
On admission, laboratory data showed normal white blood cells and platelet count, 
and slight elevation of erythrocyte sedimentation rate (18 mm/hour) and C-reactive 
protein (CRP: 1 mg/dL, normal values ,0.5 mg/dL). Serum Amyloid A (SAA) was 
normal as were creatinine, transaminases, and uric acid levels and urine analysis.
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Rheumatoid factor, as well as antinuclear, antineutrophil 
cytoplasmic, anti-Ro/La, antiendomysial, antitransglutami-
nase, and antitropheryma whipplei antibodies, was negative. 
Mild proteinuria (450 mg/24 h) was detected during an FMF 
attack. Biopsy of the periumbilical fat was negative.
Blood culture, stool examination, and culture, as well as 
urine culture were carried out because of recurrent high fever 
(39.4°C) and were negative.
Imaging studies including chest and abdominal computed 
tomography scans and echocardiography were unremarkable. 
While genetic revaluation confirmed a pM694v mutation in 
the MEFV gene, a previously undetected second mutation 
was identified in pI591T.
First of all, we increased the dose of colchicine from 1 mg 
to 2 mg daily, but this treatment was immediately discon-
tinued due to the rapid appearance of side effects (diarrhea, 
nausea, and vomiting).
We began discussing alternative treatments.
Paracetamol, corticosteroids, and nonsteroidal anti-
inflammatory drugs may sometimes be useful as analgesics 
during acute attacks, but not in this case.
On the basis of an increasing number of case reports and 
case series in which biologic drugs have been successfully 
used in the management of colchicine-resistant FMF,1,2 
we administered Anakinra (Amgen, Thousand Oaks, CA, 
USA), a recombinant, non-glycosylated form of the human 
interleukin-1 (IL-1) receptor antagonist, subcutaneously at 
a dose of 100 mg daily.
Due to the off-label use of this therapy, informed consent 
was obtained from the patient before starting treatment.
Albeit effective, anakinra was discontinued after 10 days 
due to a severe cutaneous reaction at the site of injection. The 
patient was therefore switched to canakinumab (ACZ885, 
Ilaris; Novartis Pharma, Basel, Switzerland), a fully human-
ized monoclonal antibody targeting IL-1β.3,4 This treatment 
was started in December 2010, at a dose of 150 mg given 
subcutaneously, followed by two more administrations 
8 weeks apart.
Informed consent was again provided by the patient for 
this drug before starting treatment.
The effects of canakinumab were monitored over the 
following 6-month period.
A significant improvement in the clinical symptoms was 
observed after the first administration.
During treatment with canakinumab, the patient reported 
only three minor episodes of FMF. Figure 1 shows the pro-
files of body temperature and visual analog scale.
Acute-phase reactants (CRP, erythrocyte sedimenta-
tion rate, and SAA) were evaluated every 4 weeks over a 
24-week period. These laboratory parameters normalized 
within 4 weeks.
The 36-item Short Form Health Survey (SF-36) standard 
version5,6 and the Health Assessment Questionnaire7 were used 
to monitor the patient’s health perception and physical ability.
At baseline, scores for health-related quality of life 
(HRQoL) were indicative of a reduced quality of life com-
pared with the general population.
After the first dose of canakinumab, the mean SF-36 
physical-component summary score increased from 16.6 at 
baseline to 48.8 with an increase of 32 points, and it was 47.9 
by the end of follow-up. These values approximate those of 
the general population. The mean SF-36 mental-component 
summary (MCS) also showed a significant increase over 
the course of the study from 34.2 at baseline to 57.7 after 
1 month of treatment and 60.6 at the end of the study (with 
an increase of 26.4 points from baseline). Notably, the SF-36 
MCS score at the end of the study exceeded that of the general 
population (Figure 2A).
At baseline, scores for all SF-36 individual domains were 
lower than in the general population, especially for physical 
functioning, pain, and general health (Figure 2B). Improve-
ments in score were evident for all domains by the end of 
the first month after starting therapy. Further improvements 
were observed over the entire period of monitoring, with 
mean scores approaching normal (Figure 2B).
Before starting treatment, all four subscale scores of SF-36 
mental component were lower than for the general popula-
tion and the difference was remarkable for social functioning 
(36.8 points difference) and vitality (22.9 points difference). 
After finishing treatment, all domains exceeded those of 
the general population. The greatest improvements in men-
tal functions were seen in vitality and social functioning 
(Figure 2C).
Over the course of the study, the mean Health Assessment 
Questionnaire score decreased from 2.75 at baseline to 0.0 
at the end of the study, indicating a complete remission of 
functional disability (Figure 2D).
Therapy with canakinumab for up to 24 weeks was well 
tolerated. No adverse events were observed.
Discussion
Daily administration of colchicine is the standard therapy 
for prophylaxis of FMF attacks and amyloid deposition in 
FMF.8
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Colchicine inhibits leukocyte chemotaxis through a 
direct effect on microtubuli. It also reduces the expression 
of adhesion molecules on white blood cells and endothelial 
cells, thereby interfering with leukocyte transfer to the 
inflammatory site.9
The beneficial role of colchicine in FMF attacks is well 
documented by open-label studies in adult and pediatric 
patients, as well as by placebo-controlled trials in adult 
patients.10 Long-term administration of colchicine leads to 
complete remission in two thirds of the patients and partial 
remission (defined as a significant decrease in the frequency 
of attacks or remission of a single symptom) in another third 
of the patients with FMF.10 However, a substantial minor-
ity (5%–10%) of patients does not respond to colchicine 
treatment.10
Quite recently, an increasing number of case reports 
in which biologic drugs (tumor necrosis factor-alfa, IL-6, 
and IL-1 inhibitors) have been used in the management of 
Figure 1 effect of canakinumab on thermal curves and its impact on Vas.
Notes: (A) Thermal curves of the week preceding (red line) and the week following the administration of the first dose of canakinumab (blue line). (B) Vas values of the 
week preceding (red line) and the week following the administration of the first dose of canakinumab (blue line).
Abbreviation: Vas, visual analog scale.
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patients with FMF who were unresponsive to colchicines 
have been published.
In this setting, IL-1 blockade with either anakinra or 
canakinumab has been reported in case series and both agents 
would appear to be effective.11 This year, positive results 
were published regarding the first randomized controlled 
study of an IL-1 blocker, rilonacept, in 14 colchicine-resistant 
patients.12
On the basis of the available studies, French and Israeli 
experts made evidence-based recommendations for the 
management of FMF. They recommended adding anti-IL-1 
therapy for colchicine-resistant patients and starting with a 
short half-life molecule (anakinra) to assess efficacy before 
considering long half-life IL-1-targeting therapies.2
The results of our study indicate that a single dose of 
canakinumab induces rapid remission of symptoms in 
patients with FMF, with minimal disease activity in the first 
4 weeks and sustained remission by week 8. Remission of 
symptoms was accompanied by the suppression of inflam-
mation, as indicated by the decrease until normalization of 
CRP.
FMF, like other autoinflammatory diseases, can greatly 
impact HRQoL as previously reported by in-depth interviews 
of patients with this disease.13
Our study confirms that FMF has a negative impact on the 
patient’s HRQoL, and especially on the physical component, 
and shows beneficial changes induced by canakinumab. The 
most compromised SF-36 domains in FMF were physical 
functioning, pain, and general health. Within 1 month of 
therapy, improvements were evident in all affected SF-36 
domains in agreement with the rapid remission of symptoms 
observed in the patient. Four weeks after receiving the first 
Figure 2 effects of canakinumab on HrQoL and HaQ.
Notes: (A) results of questionnaires on quality of life in relation to physical and mental health. (B) results of questionnaires on quality of life in relation to physical health, 
filled in during the course of follow-up. (C) results of questionnaires on quality of life in relation to mental health. (D) results of questionnaires on the degree of disability 
in carrying out common daily activities.
Abbreviations: PCS, physical-component summary; MCS, mental-component summary; PF, physical functioning; RP, role limitations – physical; BP, bodily pain; GH, general 
health perception; VT, vitality; SF, social functioning; RE, role limitations – emotional; MH, mental health; Mth, month; HRQoL, health-related quality of life;  HAQ, Health 
assessment Questionnaire.
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dose of canakinumab, SF-36 physical-component summary 
and SF-36 MCS scores approached those of the general 
population.
In summary, these results provide evidence that canaki-
numab induces rapid reversal of the clinical symptoms of 
FMF paralleled by a decrease in inflammation markers.
Remission can be maintained by a standard administra-
tion every 8 weeks, leading to a significant improvement in 
HRQoL scores. Notably, canakinumab 150 mg/dose is cur-
rently being investigated in FMF in a phase II clinical trial 
(trial registration: clinicaltrials.gov: NCT01088880).
Our patient has been in complete clinical remission for 
2 years, and we are considering the possibility of tapering 
therapy.
However, there is still a need for randomized controlled 
trials using canakinumab to treat FMF.
Disclosure
The authors report no conflicts of interest in this work.
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